Management of Atrial Fibrillation in Patients With Kidney Disease

Area of Science:

• Cardiology
• Nephrology
• Clinical Medicine

Background:

• Chronic Kidney Disease (CKD) poses a significant burden, with End-stage Renal Disease (ESRD) patients experiencing 10-30 times higher cardiovascular mortality than the general population.
• Atrial Fibrillation (AF), the most common cardiac arrhythmia, is frequently associated with CKD and elevates risks of stroke, heart failure, and reduced quality of life.
• Existing clinical trials for AF management, particularly stroke prevention with anticoagulation, have largely excluded patients with substantial renal impairment.

Approach:

• This review synthesizes current knowledge on stroke prevention strategies in patients with AF and CKD.
• It critically evaluates the clinical impact of CKD on AF management.
• The article discusses the implications of renal impairment for therapeutic choices and patient outcomes.

Key Points:

• Cardiovascular mortality is markedly elevated in End-stage Renal Disease (ESRD) patients.
• Atrial Fibrillation (AF) is a common comorbidity in Chronic Kidney Disease (CKD) patients, increasing thromboembolic and mortality risks.
• Exclusion of CKD patients from major AF trials complicates evidence-based stroke prevention strategies.

Conclusions:

• Effective stroke prevention in AF patients with CKD requires tailored management approaches.
• Understanding the interplay between CKD and AF is crucial for optimizing patient care and reducing adverse cardiovascular events.
• Further research is needed to address the specific needs of CKD patients in AF clinical trials and treatment guidelines.